Healthy Volunteers
Research involving healthy volunteers has expanded to investigate the therapeutic potentials of various psychedelics for mental health conditions. Recent findings, emphasizing compounds like psilocybin and DMT, illustrate a promising future for psychedelic-assisted therapies.
Key Insights
- 1
Psychedelics like psilocybin and DMT have shown promise in alleviating symptoms of depression and anxiety in healthy volunteers, highlighting their potential use in broader clinical applications.
- 2
Recent trials demonstrate that the timing and dose of psychedelics significantly influence therapeutic outcomes, suggesting optimisation could enhance efficacy.
- 3
The safety profile of psychedelics seems favourable in controlled environments, with adverse effects predominantly transient and manageable.
- 4
Research indicates that psychedelics can facilitate profound psychological insights and emotional catharsis, which are beneficial in therapeutic settings.
What is Healthy Volunteers?
Healthy volunteers are individuals who participate in clinical studies without the presence of a psychiatric or medical condition, allowing researchers to assess the effects of various compounds on both healthy and clinical populations.
The pathophysiology related to psychedelics often revolves around their action on serotonin receptors, particularly the 5-HT2A receptor, which is implicated in mood regulation, cognition, and perception.
Symptoms observed during studies often include altered states of consciousness, emotional release, and subjective feelings of interconnectedness, varying widely depending on the psychedelic used.
Healthy volunteers are essential for baseline assessments to evaluate the safety and efficacy of psychedelics prior to their application in individuals with severe psychiatric disorders.
Current Treatments
Current treatments for mental health conditions predominantly include pharmacotherapy (SSRIs, SNRIs) and psychotherapy, but psychedelic-assisted therapy is gaining traction as an alternative or adjunct to these methods.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Healthy Volunteers.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Meta-analyses consistently report on psilocybin's efficacy in reducing depression in both healthy volunteers and clinical populations. | Large | High | Consistent |
| DMT Studies show significant mental health benefits, particularly in anxiety reduction, although more evidence is needed on long-term effects. | Medium | Moderate | Consistent |
| 5-MeO-DMT While some studies indicate strong psychological relief, discrepancies in methodology hinder firm conclusions. | Medium | Moderate | Inconsistent |
| MDMA Extensive testing shows MDMA significantly reduces PTSD symptoms, indicating its therapeutic potential. | Large | High | Consistent |
| Ketamine Proven to rapidly relieve depression symptoms with consistent efficacy across trials. | Large | High | Consistent |
Psilocybin and Healthy Volunteers
Psilocybin is a classic psychedelic known for its ability to induce altered states of consciousness. In healthy volunteers, it has demonstrated significant effects on mood, promoting feelings of wellbeing and reducing anxiety and depression, largely through its agonistic action on serotonin receptors, particularly 5-HT2A.
Research shows that psilocybin can facilitate profound psychological insights, emotional release, and improved life satisfaction, indicating its potential in therapeutic settings for psychological distress.
DMT and Healthy Volunteers
DMT, a powerful psychedelic, induces intense and vivid experiences that can lead to lasting changes in perception and emotional health. In studies involving healthy volunteers, it has been linked with rapid reductions in anxiety and mood improvement, suggesting its short-term use may be beneficial for significant mood enhancement.
The subjective experiences reported by participants often include feelings of unity and interconnectedness, which may contribute to lasting positive changes in mental health, indicating its potential in therapeutic applications.
Clinical Outlook
The future of psychedelic treatment for mental health conditions seems increasingly optimistic as research continues to uncover the potential of these compounds in promoting psychological healing. Ongoing studies with healthy volunteers will be critical to establish safety, dosage, and standardized protocols necessary for eventual clinical application.
Industrial Landscape
Key industry players include major pharmaceutical companies engaged in drug development, academic institutions conducting pivotal research, and non-profits such as the Multidisciplinary Association for Psychedelic Studies (MAPS) which advocate for psychedelic research and education.
Quick Indicators
Organisations
Search →Janssen Research & Development
Janssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
Algernon Pharmaceuticals
Algernon Pharmaceuticals (also known as Algernon Health / Algernon NeuroScience) is the first company in the world to test DMT as an emergent treatment for ischemic stroke and traumatic brain injury. Their lead candidate AP-188 uses sub-hallucinogenic IV DMT to promote neuroplasticity and neuroprotection. Phase 1 completed at the Centre for Human Drug Research in Leiden; Phase 2a stroke trial planned.
Cybin
Cybin Inc. (founded 2019) is a Canadian clinical-stage biopharmaceutical company developing psychedelic-based therapeutics—now operating as Helus Pharma—focused on proprietary novel serotonergic agonists and deuterated psilocin analogs for mental health conditions.
Ohio State University
The Ohio State University is a public land-grant research university based in Columbus, Ohio, offering undergraduate, graduate, and professional programs and conducting research across many fields. It was founded as the Ohio Agricultural and Mechanical College and serves as a major educational and economic institution in Ohio.
Dana-Farber Cancer Institute
Definium Therapeutics
Definium Therapeutics (formerly Mind Medicine / MindMed) is a late-stage clinical biopharmaceutical company headquartered in New York, founded in 2019 and rebranded in January 2026. Led by CEO Robert Barrow, the company applies scientific rigor to psychedelic-derived molecules to develop accessible, rapidly-acting psychiatric treatments. Its lead asset, DT120 ODT (formerly MM-120) — a pharmaceutically optimised formulation of lysergide D-tartrate (LSD) as an orally disintegrating tablet — has received FDA Breakthrough Therapy Designation for generalised anxiety disorder (GAD) and delivered compelling Phase 2b results: 65% clinical response rate and 48% remission at 12 weeks following a single dose. Three Phase 3 trials are currently underway: Voyage and Panorama (GAD) and Emerge (MDD, fully enrolled). Topline data from all three studies is expected in 2026, potentially positioning Definium for the first-ever FDA approval of an LSD-derived therapy. A second pipeline asset, DT402 (formerly MM402) — an MDMA-related compound — is in Phase 1 development for autism spectrum disorder.
Lobe Sciences
Canadian psychedelic biotech developing conjugated psilocin formulations for treatment-resistant conditions. Spun out its proprietary Conjugated Psilocin™ technology to Cynaptec Pharmaceuticals in April 2025 via an $8.46 million financing round. Lead programme L-130 targets cluster headache disorder.
National Institute on Drug Abuse (NIDA)
U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.
Optimi Health
Canadian GMP-certified manufacturer of pharmaceutical-grade psilocybin and MDMA, licensed by Health Canada. Optimi's facility in Princeton, British Columbia is one of the largest legal psilocybin production operations in North America. Supplies clinical trial material to researchers in Australia, Israel, and Canada.
MycoMedica Life Sciences
MycoMedica Life Sciences PBC is a public benefit corporation developing low-dose psilocybin medicines for psychiatric and neurological disorders. Their lead candidate MLS101 is in Phase 1 clinical development, with PMDD as the lead indication and OUD and OCD as additional targets. Based in Shelton, Washington.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Resilient Pharmaceuticals
Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) is a US-based public benefit corporation developing MDMA-assisted therapy for PTSD. It was founded in 2014 by MAPS (Multidisciplinary Association for Psychedelic Studies) as a commercial spinout to carry MAPS’ three decades of MDMA research through late-stage trials and regulatory approval. After completing two Phase 3 trials and filing an NDA in 2024, the FDA issued a Complete Response Letter (CRL) in August 2024, citing concerns about functional unblinding, durability of response, safety reporting at two trial sites, and the challenge of blinding psychedelic studies. The CRL requested a third Phase 3 trial. Following the rejection, the company laid off approximately 75% of staff. In May 2025, billionaire investors Antonio Gracias (Gracias Foundation) and Sir Christopher Hohn (TCI Fund) led a $50 million Series B recapitalisation, installing new leadership: CEO Mike Burke and CMO Javier Muniz. Rick Doblin, MAPS’ founder, remains supportive of the new direction. The company rebranded from Lykos Therapeutics to Resilient Pharmaceuticals on 28 August 2025, and continues to negotiate a path to FDA approval for MDMA-assisted therapy for PTSD.
People
Search →Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Eduardo Schenberg
Neuroscientist and founder/director of Instituto Phaneros
A leading Brazilian psychedelic researcher known for clinical and translational work on ayahuasca, ibogaine, MDMA, and ethics/policy in psychedelic medicine.
Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Erich Studerus
Psychologist and Scientific Director at fepsy Basel; Lecturer at FHNW
He is a recurring author on influential human psychedelic studies, especially on psilocybin, LSD, MDMA, and ayahuasca effects and predictors of response.
Connected Evidence
The latest clinical data and verified academic findings associated with Healthy Volunteers.